Clinical Trials Browser

OTHER × axicabtagene ciloleucel × Clear all

NCT06043323 2026-03-12

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma

Phase 2 Recruiting

Lymphoma, Follicular

NCT07042438 2026-03-05

Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04205838 2026-02-27

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

Phase 2 Terminated

Lymphoma, Large B-Cell, Diffuse, Disease Progression

NCT05757219 2026-02-27

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07052305 2026-02-12

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Phase 1 Recruiting

Lymphoma, Non-Hodgkin

NCT03642626 2026-01-23

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Phase 2 Active not recruiting

150 enrolled 23 charts

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04855253 2026-01-15

Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL

Phase 1/2 Suspended

Lymphoma, Large B-Cell, Diffuse

NCT06213311 2026-01-14

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

Phase 2 Recruiting

Lymphoma, B-Cell

NCT07326371 2026-01-08

Glofitamab Combined With CAR-T Therapy in R/R DLBCL

Phase 2 Not yet recruiting

Dendritic Cell Sarcoma, Interdigitating

NCT07254754 2025-11-28

LATE-R-GEL-23

Phase 2 Recruiting

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04150913 2025-11-25

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Phase 2 Completed

15 enrolled 17 charts

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Neurotoxicity Syndromes

NCT06550141 2025-11-14

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Phase 2 Recruiting

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05794958 2025-09-23

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

Phase 1 Recruiting

Lymphoma, Non-Hodgkin

NCT04608487 2025-07-30

Axi-cel in CNS Lymphoma

Phase 1 Active not recruiting

Lymphoma, Recurrence

NCT05108805 2025-03-27

Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting

Phase 4 Completed

25 enrolled 17 charts

Lymphoma, Large B-Cell, Diffuse

NCT06826118 2025-02-13

Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma

Phase 2 Recruiting

Lymphoma, Lymphoma, Follicular

NCT04432506 2025-01-28

Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

Phase 2 Completed

22 enrolled 15 charts

LymphoidOther hematologic neoplasm

Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

NCT06609304 2024-10-15

axi-cel

Phase 4 Recruiting

Lymphoma, B-Cell